NZ711210B2 - Combination therapy for neoplasia treatment - Google Patents
Combination therapy for neoplasia treatment Download PDFInfo
- Publication number
- NZ711210B2 NZ711210B2 NZ711210A NZ71121014A NZ711210B2 NZ 711210 B2 NZ711210 B2 NZ 711210B2 NZ 711210 A NZ711210 A NZ 711210A NZ 71121014 A NZ71121014 A NZ 71121014A NZ 711210 B2 NZ711210 B2 NZ 711210B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- antibody
- heavy chain
- light chain
- igf
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 80
- 206010028980 Neoplasm Diseases 0.000 title claims description 41
- 230000009826 neoplastic cell growth Effects 0.000 title claims description 6
- 238000002648 combination therapy Methods 0.000 title description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 185
- 102000013275 Somatomedins Human genes 0.000 claims abstract description 174
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 86
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 85
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical group C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims abstract description 66
- 229960004671 enzalutamide Drugs 0.000 claims abstract description 63
- 229940044551 receptor antagonist Drugs 0.000 claims abstract description 44
- 239000002464 receptor antagonist Substances 0.000 claims abstract description 44
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 26
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 26
- 206010029096 Neoplasm prostate Diseases 0.000 claims abstract description 20
- 239000005557 antagonist Substances 0.000 claims abstract description 14
- 239000003098 androgen Substances 0.000 claims description 35
- 230000000295 complement effect Effects 0.000 claims description 20
- 229960004103 abiraterone acetate Drugs 0.000 claims description 16
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- BUJCVBRLTBAYCW-UHFFFAOYSA-N 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxyphenoxy)propan-1-one Chemical compound COC1=CC=CC=C1OC(CO)C(=O)C1=CC=C(O)C(OC)=C1 BUJCVBRLTBAYCW-UHFFFAOYSA-N 0.000 claims description 3
- 241001523179 Lasia <small-headed fly> Species 0.000 claims description 3
- 229940123407 Androgen receptor antagonist Drugs 0.000 abstract description 23
- 239000003936 androgen receptor antagonist Substances 0.000 abstract description 21
- 210000004027 cell Anatomy 0.000 description 100
- 239000003795 chemical substances by application Substances 0.000 description 39
- 201000011510 cancer Diseases 0.000 description 35
- 108010080146 androgen receptors Proteins 0.000 description 31
- 102100032187 Androgen receptor Human genes 0.000 description 30
- 239000003446 ligand Substances 0.000 description 30
- 230000000694 effects Effects 0.000 description 26
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 108091008611 Protein Kinase B Proteins 0.000 description 16
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- 210000002307 prostate Anatomy 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 12
- 238000006366 phosphorylation reaction Methods 0.000 description 12
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 9
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 9
- 230000005754 cellular signaling Effects 0.000 description 9
- 229960003668 docetaxel Drugs 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 108090000397 Caspase 3 Proteins 0.000 description 7
- 102100029855 Caspase-3 Human genes 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 7
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 7
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 7
- 229960000853 abiraterone Drugs 0.000 description 7
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- -1 ketonazole Chemical compound 0.000 description 7
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 229940030486 androgens Drugs 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 4
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 229960003473 androstanolone Drugs 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 102000047934 Caspase-3/7 Human genes 0.000 description 3
- 108700037887 Caspase-3/7 Proteins 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 108090000257 Cyclin E Proteins 0.000 description 3
- 102000003909 Cyclin E Human genes 0.000 description 3
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 3
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 3
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000002280 anti-androgenic effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000051 antiandrogen Substances 0.000 description 3
- 239000012911 assay medium Substances 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000007469 bone scintigraphy Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960001573 cabazitaxel Drugs 0.000 description 3
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- WQBIOEFDDDEARX-CHWSQXEVSA-N (4ar,10br)-8-chloro-4-methyl-1,2,4a,5,6,10b-hexahydrobenzo[f]quinolin-3-one Chemical compound C1CC2=CC(Cl)=CC=C2[C@@H]2[C@@H]1N(C)C(=O)CC2 WQBIOEFDDDEARX-CHWSQXEVSA-N 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OZPFIJIOIVJZMN-SFHVURJKSA-N 6-[(7s)-7-hydroxy-5,6-dihydropyrrolo[1,2-c]imidazol-7-yl]-n-methylnaphthalene-2-carboxamide Chemical compound C1=CC2=CC(C(=O)NC)=CC=C2C=C1[C@]1(O)C2=CN=CN2CC1 OZPFIJIOIVJZMN-SFHVURJKSA-N 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102100021719 Steroid 17-alpha-hydroxylase/17,20 lyase Human genes 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 229950008527 bexlosteride Drugs 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 229960004199 dutasteride Drugs 0.000 description 2
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002913 goserelin Drugs 0.000 description 2
- 108700020746 histrelin Proteins 0.000 description 2
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 2
- 229960002193 histrelin Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 2
- 229960002653 nilutamide Drugs 0.000 description 2
- 229950004023 orteronel Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229960000714 sipuleucel-t Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004824 triptorelin Drugs 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- WMPQMBUXZHMEFZ-YJPJVVPASA-N turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 description 2
- 229950007816 turosteride Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229940085728 xtandi Drugs 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 101150034533 ATIC gene Proteins 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229940127512 Androgen Synthesis Inhibitors Drugs 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 208000004766 Cytochrome P-450 CYP2C8 Inducers Diseases 0.000 description 1
- 208000006619 Cytochrome P-450 CYP2C8 Inhibitors Diseases 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 1
- 101000896517 Homo sapiens Steroid 17-alpha-hydroxylase/17,20 lyase Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 1
- VMGWGDPZHXPFTC-HYBUGGRVSA-N Izonsteride Chemical compound CN([C@@H]1CCC2=C3)C(=O)CC[C@]1(C)C2=CC=C3SC(S1)=NC2=C1C=CC=C2CC VMGWGDPZHXPFTC-HYBUGGRVSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- 101710163849 Steroid 17-alpha-hydroxylase/17,20 lyase Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102100030859 Tissue factor Human genes 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000453 cell autonomous effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000015700 familial long QT syndrome Diseases 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002665 ion therapy Methods 0.000 description 1
- 229950004319 izonsteride Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229950001762 linsitinib Drugs 0.000 description 1
- PKCDDUHJAFVJJB-VLZXCDOPSA-N linsitinib Chemical group C1[C@](C)(O)C[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N PKCDDUHJAFVJJB-VLZXCDOPSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007434 lytic lesion Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- AMLJWLYRONUCKO-UHFFFAOYSA-N n-(6-amino-5-iodopyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC=C(I)C(N)=N1 AMLJWLYRONUCKO-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108091008581 nuclear androgen receptors Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003217 oral combined contraceptive Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide. onist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.
Description
PCT /EP2014/054300 Combination therapy for neoplasia treatment The present invention relates to the pharmaceutical treatment of neoplasia, including benign and malignant tumors.
Background of the invention Prostate cancer is the most common malignancy diagnosed in males and a leading cause of mortality in western countries can Cancer y, 2010 (http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-026238.pdf)). Androgens and stimulation of their receptor, androgen receptor (AR), are essential for the development and function of the normal prostate gland, and the development and progression of prostate cancer (reviewed in Basu S et al., Horm Cancer. 2010 Oct;1 (5):223-8.; Yadav N et al., Minerva Urol Nefrol. 2012 Mar;64(1):35-49). For metastatic te cancer, androgen deprivation therapy remains the standard treatment. e the fact that initially more than 90% of patients respond to androgen deprivation y, the clinical ts are temporary with tumors becoming refractory and progressing to androgen-independent/castration-resistant prostate cancer (CRPC) (Rini Bl et al., Curr Treat Options Oncol. 2002 Oct;3(5):437-46.; Carles J et al., Clin Transl Oncol. 2012 Mar;14(3):169-76). CRPC is associated with continued androgen or (AR) activation despite hormonal tion and/or treatment with currently available anti-androgens. The molecular ism of androgen stimulation of prostate cancer growth and the switch to androgen independence is not fully clear. The progression to androgen independence may be explained by s with the androgen receptor, such as amplification, mutations, or d activity of splice variants. Other possible mechanisms include tumor cell autonomous production of androgens, ligand-independent activation of AR by kinases like ERK or AKT (reviewed in Dutt SS et al., Future Oncol. 2009 Nov;5(9):1403-13. and Attar RM et al., Clin Cancer Res. 2009 May ;15(10):3251-5) or that androgens may regulate te cancer proliferation by up-regulating autocrine loops involving peptide growth factors and their cognate receptors (De Bellis A et al., J Clin Endocrinol Metab 1:4148—54.). All these mechanisms could result in independence to endocrine ens.
Benign prostatic hyperplasia (BPH) can be detected in the vast majority of men as they age (Parsons JK., Curr Bladder Dysfunct Rep. 2010 Dec;5(4):212—218). BPH can be defined as a non-cancerous enlargement of the prostate resulting from a proliferation of both benign stromal, and to a lesser extent, epithelial cells (Foster CS. Prostate 2000;9:4—14.). In both of these cell types, dihydrotestosterone (DHT), a metabolite of testosterone that is 10 times more potent e it dissociates from the androgen receptor more slowly than testosterone, binds to nuclear androgen receptors resulting in the transcription of growth factors that are mitogenic to the epithelial and stromal cells. In the prostate, testosterone is converted to DHT by the enzyme 5d-reductase, type 2. In the condition of BPH, local testosterone levels can be elevated more than 100-fold above serum levels leading to an increased availability of DHT (Gat Y et al., Andrologia 2008 (5):273-81). Therapy with 5d-reductase inhibitors, such as finasteride, markedly reduces the DHT t of the prostate and, in turn, s prostate volume and, in many cases, BPH symptoms. Androgens are t to be essential for BPH to occur, but do not seem to be the only cause for the condition.
Insulin-like growth factors(lGFs) and their binding proteins may play an important role in tanding the etiology of prostate disease, including BPH. Several lines of ce support involvementof the IGF axis in BPH. IGF ligands have mitogenic effects on the prostate, while IGF binding proteins (lGFBPs) are growth inhibitory due to their ability to regulate availability of the lGFs, other growth factors, and steroid hormones (Pollak MN et al, Nat Rev 2004;4:505—518.).
IGFBP3 is secreted at particularly low levels in stromal cells in BPH tissue (Boudon C et al., J Clin Endocrinol Metab 1996;81:612—617.) which may favor hyperplastic growth and play a role in the development of BPH. Moreover, acromegalic patients, who have very high levels of IGF1 and itantly low levels of testosterone and DHT, present with enlarged prostates and high rates of BPH (Colao A et al J Clin Endocrinol Metab 1999;84:1986—1991; Colao A et al, Eur J Endocrinol 2000;143:61—69.).
The n-like growth factor (IGF) system plays a key role in stimulating proliferation and survival of both normal tissues and cancers (reviewed in LeRoith D, Roberts CT Jr., Cancer Lett 95:127—37). High circulating lGF-1 concentrations have been associated with increased risk for te cancer in several clinical and epidemiologic studies (Price AJ et al., Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1531-41; Roddam AW et al., Ann Intern Med 2008;149(7):461-71). In prostate epithelial cells, increased lGF-1 expression was shown to lead to higher rates of proliferation and/or lower rates of apoptosis (Takahara K et al., Prostate. 2011 Apr;71(5):525-37). Loss of imprinting of the lGF-2 locus and increased expression of lGF-2 are observed in many cancers including prostate cancer (Jarrard DF et al., al Cancer ch 1995;1, 1471—1478.; Fu VX et al., Cancer Research 2008;68, 6797—6802) and may be related to the risk to develop prostate cancer (Belharazem D et al, Endocrine Connections 2012;1, 87—94). Furthermore, not only expression of lGF-1 and lGF-2 ligands but also their receptor, lGF-1 R, has been shown to be elevated in ed prostate tumors (Cardillo, MR et al., Anticancer Res. 2003 23, 3825— 3835; Liao, Y et al., Hum. Pathol. 2005;36 (11), 1186— 1196; Hellawell GO et al., Cancer Res. 2002 May 10):2942-50; Turney BW et al., BJU Int. 2011 May;107(9):1488—99; Krueckl SL et al., Cancer Res. 2004 Dec 1;64(23):8620-9; Figueroa, JA et al., Cancer Invest. 2001 ;19 (1), 28—34; Ryan, CJ et al., . Urol.
Oncol. 2007;25, 134—140). In recurrent and androgen-independent cancer, an increase also in AKT phosphorylation was demonstrated (Graff JR et al.,. J. Biol.
Chem 2000;275: 24500—5; Murillo H et al., Endocrinology 2001;142: 05.) Castration-resistant prostate cancer has been shown to be sensitive, but not resistant, to sustained manipulation of the androgen/AR axis. The androgen axis can be manipulated using anti-androgens (nilutamide, tamide), androgen sis tors (ketonazole, abiraterone acetate), corticosteroids (dexamethasone, prednisone) or estrogen treatment. ing the emergence of castration-refractory disease, taxane-based chemotherapy has been shown to be therapeutically efficacious and prolong survival. Patients progressing on docetaxel have been shown to benefit from abiraterone acetate, a selective cytochrome P450 17A1 inhibitor which requires inistration with glucocorticoids to l side effects. Enzalutamide (MDV-3100) is a novel AR antagonist that blocks AR ing more effectively than currently available AR antagonists (Tran et al., Science 2009;324(5928): 787-790.) and has shown impressive antitumor activity and a similar impact on overall al as abiraterone.
Antagonists to IGF action and their use in cancer y have been described in the art. For disclosure of IGF receptor tyrosine kinase inhibitors, see WO2009/009016 and WO2010/099139. For disclosure of dies against IGF receptor, see WO2002/53596, WO2003/093317, WO2003/106621, WO2006/013472, WO2006/069202. For disclosure of dies against IGF ligand, see WO2003/093317, WO2005/028515, WO2007/022172, WO2007/070432, WO2008/155387, WO2009/137758, WO2010/066868. IGF-1 receptor antibodies, WO2008/098917, WO2009/137378) and IGF ligand antibodies (WO2007/1 18214, WO2008/155387, WO2009/137758, WO2010/066868) have been proposed for use, inter alia, in the treatment of prostate .
The state of the art is also discussed in further publications (Pollak MN et al., Cancer Metastasis Rev 1998;17:383—90; Djavan B et al., World J Urol 2001;19:225—33; Wolk A et al., J Natl Cancer Inst 1998;90:911—5; Jiang YG et al., Int. J. Urol. 2007;14:1034—9; Lin HK et al., Proc. Natl Acad. Sci. USA 2001;98: ; Wen Y et al., Cancer Res. 2000;60: 6841—5; Plymate SR et al., Prostate 2004;61:276—90; AA Lubik et al., Endocr Relat Cancer ERC0250 2013, first published on 14 January ; Nickerson T et al. Cancer Res. 2001 ;61 (16), 6276— 6280; Pandini G et al., Cancer Res., 2005 March 1;65; 1849; Bedolla R et al. Clin Cancer Res. 2007 Jul 1;13(13):3860-7; Carver BS et al., Cancer Cell 2011 May 17;19, 575—586; Mulholland DJ et al., Cancer Cell, 2011 June 14;19, 792—804) Despite advances made in the early detection and treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and ularly CRPC, there is a significant need for improvements in therapy.
Brief ption of the Figures Figure 1. Inhibitory effect of IGF and AR signaling blockade on VCaP, MDA PCa 2b and DUCaP cell proliferation VCaP, MDA PCa 2b and DUCaP cells were treated with MDV-3100 and IGF ligand-neutralizing antibodies as single agents and in combination. Figure 1 shows the inhibitory effect of the IGF mAb_1 (Fig. 1A + 1C + 1E) and IGF mAb_2 (Fig. 18 + 1D + 1F) antibodies and MDV-3100, alone and in combination, on the 2D proliferation of prostate cancer-derived VCaP cells (Fig. 1A + 18), MDA PCa 2b cells (Fig. 1C + 1D) and DUCaP cells (Fig. 1E + 1F) in 10% FCS—containing growth medium. In all three cell lines, single agent ent with both IGF antibodies and MDV-3100 resulted in inhibition of cell proliferation which could be enhanced by the combination of both agents leading to a complete inhibition of proliferation.
Figure 2. Inhibitory effect of IGF signaling and androgen synthesis blockade on VCaP, MDA PCa 2b and DUCaP cell proliferation Figure 2 demonstrates the effects of the IGF mAb_1 and IGF mAb_2 dies and abiraterone acetate (AA), as single agents and in ation, on the 2D and 3D proliferation of prostate cancer-derived VCaP, MDA PCa 2b, and DUCaP cells in 10% FCS—containing growth medium. Panel (A) displays the s of the treatment of VCaP cells with IGF mAb_1 in 2D cell proliferation assays. IGF mAb_2 was used for the treatment of VCaP cells in (B). Panel C (IGF mAb_1) and D (IGF mAb_2) show the results of MDA PCa 2b cells. The treatment of DUCaP cells with IGF mAb_1 is displayed in panel E and with IGF mAb_2 in panel F.
Single agent treatment with IGF mAb_1 and mAb_2 resulted in inhibition of cell proliferation of 70% to 90%. Abiraterone acetate treatment caused inhibition of cell eration at higher concentrations which could be ed by the combination with either of the antibodies, lowering the doses of AA needed for complete inhibition. In a 3D soft agar cell proliferation assay (G), VCaP cells were treated with abiraterone acetate and IGF mAb_2. Similar to the results observed in 2D, single agent treatment with IGF mAb_2 results in 96% inhibition of cell proliferation. Abiraterone acetate treatment caused inhibition of cell proliferation at higher trations which could be enhanced by the combination with IGF mAb_2.
Figure 3. Protein analysis in VCaP, MDA PCa 2b and DUCaP cells following IGF and AR ing inhibition Figure 3 shows the effects of IGF mAb_1 and MDV-3100, alone and in combination, on IGF-1 R, AR and PTEN levels, as well as AKT phosphorylation, in VCaP, MDA PCa 2b and DUCaP cells as assessed by Western blot es.
Cells were seeded in 6-well plates and treated for 24 hours. (A) Lysates prepared from treated VCaP cells were compared to untreated controls and insensitive PC-3 cells for protein expression of IGF-1 R, AR, PTEN and AKT and for phosphorylation of AKT-Ser473. Protein expression and AKT phosphorylation of untreated and treated MDA PCa 2b (B) and DUCaP (C) cells were ted and compared to that of VCaP cells. Untreated PC-3 cells served as a control. lmportantly, VCaP, MDA PCa 2b, and DUCaP cells were shown to express the lGF1-R, AR and PTEN, unlike the insensitive cell line PC-3. MDV-3100 treatment slightly increased AR protein levels which may be due to stabilization of the n. Concomitantly, IGF-1 R levels were slightly decreased upon MDV-3100 treatment. The combination of both agents resulted in a more complete inhibition of AKT phosphorylation than the antibody or MDV-3100 treatment alone.
Figure 4. IGF signaling pathway inhibition following single agent and combination treatment of IGF mAb_1 and MDV-3100.
Figure 4 trates the effects of IGF mAb_1 and MDV-3100 used as single agents and in combination on IGF-1 R levels and AKT phosphorylation in VCaP cells over 120 hours of ent. VCaP cells were seeded in 6-well plates and treated with MDV-3100 and IGF mAb_1 as single agents or in combination for 24, 48, 72, 96, and 120 hours. Lysates prepared from treated cells were ed to untreated controls for phosphorylation of AKT-Ser473. Combination of both agents resulted in a longer lasting inhibition of AKT phosphorylation than the antibody or 00 treatments alone.
Figure 5. Reduced proliferative activity of VCaP cells following single agent and combination treatment of IGF mAb_1 and MDV-3100 eration of VCAP cells was monitored using a H3-thymidine incorporation assay. Treated with 10 pM of MDV-3100 or 1 pM of IGF mAb_1 as single agents for 96 hours reduced erative activity by approximately 50%. Combination of IGF mAb_1 and MDV-3100 reduced thymidine incorporation by more than 95% compared to untreated controls.
Figure 6. Diminished growth rate of VCaP cells following single agent and ation ent of IGF mAb_1 and MDV-3100 (A) Effect of 1 pM of IGF mAb_1 and 10 pM of MDV-3100 used as single agents and in ation on cell morphology and cell growth as observed in microscopic analyses. (B) Effect of 10 pM of MDV-3100 on the generation time of VCaP cells compared to untreated controls.
Figure 7. Combination treatment of IGF mAb_1 and MDV-3100 ses induction of apoptosis in VCaP cells Caspase 3 activity was used as a measure of the induction of apoptosis in VCaP cells upon treatment with 10 pM of MDV-3100 and 1 pM of mAb as single agents and in combination for up to 96 hours. Wheras MDV-3100 treatment did not induce caspase 3 activity within 96 hours of treatment, an increase in apoptotic events were ed upon treatmen with IGF mAb_1. The combination of both agents showed a synergistic effect on the induction of caspase 3 activity, which was appoximately 9-fold increased ed to controls and approximately 25-fold higher compared to IGF mAb_1 treatment.
Figure 8. Cell cycle profiles of VCaP cells d with MDV-3100 and IGF mAb_1 The cell cycle profiles of VCaP cells after 24 h, 48 h and 72 h of treatment with 10 pM of MDV-3100 and 1 pM of mAb as single agents and in combination as determined by propidium iodide staining detected by flow cytometry. The first population to the left is the sub-G1 population representing apoptotic cells, the second population shows the G1/G0 peak, the light grey population shows cells in the S-phase, and the population to the right represents cells in the G2/M-phase of the cell cycle. In VCaP cells treated with IGF mAb_1, and to a greater extent in cells treated with the combination of IGF mAb_1 and MDV-3100 the tic cell population increases with time, wheras in VCaP cells treated with MDV-3100 this population does not change. Instead, MDV-3100 treatment increased the G1/G0 population compared to untreated ls.
Figure 9. Protein analysis of apoptosis and cell cycle regulators following IGF signaling inhibition The effects of the treatment with 10 µM of 00 and 1 µM of IGF mAb_1 as single agents and in combination on AKT phosphorylation, PARP cleavage, p21, CDK2, Cyclin E, and PCNA levels after 8h, 24h, 48h and 72h of treatment where ed by Western blot analysis. IGF mAb_1 treatment led to blockade of AKT phosphorylation, and combined IGF mAb_1 and MDV-3100 treatment increased PARP cleavage and Cyclin E levels while it reduced CDK2 and PCNA levels. MDV- 3100 treatment increased p21 levels at 8 and 24 hours.
Brief description of the invention In a first aspect of the invention, there is provided use of an insulin-like growth factor (IGF) receptor nist in the manufacture of a medicament for the treatment of prostate neoplasia, wherein the ment is ated for stration in combination with an androgen receptor antagonist selected from enzalutamide and abiraterone acetate, wherein the IGF receptor antagonist is an antibody having heavy chain complementary determining s of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3) and light chain determining regions of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3), or an antibody having heavy chain complementary determining s of SEQ ID NO: 11 (HCDR1), SEQ ID NO: 12 (HCDR2), and SEQ ID NO: 13 (HCDR3) and light chain determining regions of SEQ ID NO: 14 (LCDR1), SEQ ID NO: 15 (LCDR2), and SEQ ID NO: 16 (LCDR3), or an antibody having heavy chain mentary determining regions of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2), and SEQ ID NO: 23 (HCDR3) and light chain determining s of SEQ ID NO: 24 (LCDR1), SEQ ID NO: 25 (LCDR2), and SEQ ID NO: 26 (LCDR3), ), or an antibody having heavy chain complementary determining regions of SEQ ID NO: 31 ), SEQ ID NO: 32 (HCDR2), and SEQ ID NO: 33 (HCDR3) and light chain determining regions of SEQ ID NO: 34 (LCDR1), SEQ ID NO: 35 (LCDR2), and SEQ ID NO: 36 (LCDR3), or an antibody having a heavy chain variable region of SEQ ID NO: 7 and a light chain variable region of SEQ ID NO: 8, or an antibody having a heavy chain variable region of SEQ ID NO: 17 and a light chain le region of SEQ ID NO: 18, ), or an antibody having a heavy chain variable region of SEQ ID NO: 27 and a light chain variable region of SEQ ID NO: 28, ), or an antibody having a heavy chain variable region of SEQ ID NO: 37 and a light chain variable region of SEQ ID NO: 38, ), or an dy having a heavy chain variable region of SEQ ID NO: 41 and a light chain variable region of SEQ ID NO: 42, ), or an antibody having a heavy chain variable region of SEQ ID NO: 43 and a light chain variable region of SEQ ID NO: 44, or an antibody having a heavy chain of SEQ ID NO: 9, and a light chain of SEQ ID NO: 10, or an antibody having a heavy chain of SEQ ID NO: 19, and a light chain of SEQ ID NO: 20, or an antibody having a heavy chain of SEQ ID NO: 29, and a light chain of SEQ ID NO: 30, or an antibody having a heavy chain of SEQ ID NO: 39, and a light chain of SEQ ID NO: 40.
In a second aspect of the ion, there is provided use of an androgen or antagonist selected from enzalutamide and abiraterone acetate in the manufacture of a medicament for the treatment of prostate neoplasia, wherein the medicament is formulated for administration in ation with an IGF receptor antagonist, wherein the IGF receptor antagonist is an antibody having heavy chain complementary determining regions of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3) and light chain determining regions of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3), or an antibody having heavy chain complementary determining regions of SEQ ID NO: 11 (HCDR1), SEQ ID NO: 12 (HCDR2), and SEQ ID NO: 13 (HCDR3) and light chain determining regions of SEQ ID NO: 14 (LCDR1), SEQ ID NO: 15 (LCDR2), and SEQ ID NO: 16 (LCDR3), or an antibody having heavy chain complementary ining s of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2), and SEQ ID NO: 23 (HCDR3) and light chain determining regions of SEQ ID NO: 24 (LCDR1), SEQ ID NO: 25 (LCDR2), and SEQ ID NO: 26 (LCDR3), ), or an antibody having heavy chain complementary determining regions of SEQ ID NO: 31 (HCDR1), SEQ ID NO: 32 (HCDR2), and SEQ ID NO: 33 (HCDR3) and light chain determining regions of SEQ ID NO: 34 (LCDR1), SEQ ID NO: 35 (LCDR2), and SEQ ID NO: 36 (LCDR3), or an antibody having a heavy chain variable region of SEQ ID NO: 7 and a light chain variable region of SEQ ID NO: 8, or an antibody having a heavy chain variable region of SEQ ID NO: 17 and a light chain variable region of SEQ ID NO: 18, ), or an antibody having a heavy chain variable region of SEQ ID NO: 27 and a light chain variable region of SEQ ID NO: 28, ), or an antibody having a heavy chain variable region of SEQ ID NO: 37 and a light chain variable region of SEQ ID NO: 38, ), or an antibody having a heavy chain variable region of SEQ ID NO: 41 and a light chain variable region of SEQ ID NO: 42, ), or an antibody having a heavy chain variable region of SEQ ID NO: 43 and a light chain variable region of SEQ ID NO: 44, or an antibody having a heavy chain of SEQ ID NO: 9, and a light chain of SEQ ID NO: 10, or an antibody having a heavy chain of SEQ ID NO: 19, and a light chain of SEQ ID NO: 20, or an antibody having a heavy chain of SEQ ID NO: 29, and a light chain of SEQ ID NO: 30, or an antibody having a heavy chain of SEQ ID NO: 39, and a light chain of SEQ ID NO: 40.
In a further aspect, the present ion pertains to an insulin-like growth factor (IGF) receptor nist for use in the treatment of prostate neoplasia, ing benign tic lasia (BPH), prostate cancer, and particularly CRPC in combination with an androgen receptor antagonist.
In another embodiment, the invention relates to a method of treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate , and particularly CRPC comprising administering a therapeutically effective amount of an IGF receptor antagonist to a patient in need thereof, and additionally administering a therapeutically ive amount of an androgen receptor PCT /EP2014/054300 antagonist to the same patient on the same day, or one, two, three, four, five, six or seven days before or after admistration of the IGF receptor antagonist.
Detailed description of the ion The present invention relates to the treatment of prostate neoplasia.
By "prostate neoplasia", the aspects of the invention include where the prostate neoplasia is prostate cancer, including benign and malignant tumours, and particularly castration resistant prostate cancer; and also benign prostatic hyperplasia.
In one aspect, the t invention pertains to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate cancer. In r embodiment, the prostate cancer is hormone-sensitive prostate cancer. In another embodiment, the te cancer is prostate cancer after combined androgen blockade. In another embodiment, the prostate cancer is prostate cancer treated with antiangiogenic therapy. In another embodiment the prostate cancer has been, or will be, treated with a chemotherapeutic agent. In another embodiment, the prostate cancer is prostate cancer treated, or will be treated, with ion therapy. In another embodiment, the prostate cancer is prostate cancer treated, or will be treated, with bone loss therapy, for example mab, and e ablation.
In another embodiment, the prostate cancer is castration ant prostate cancer (CRPC). In another embodiment the castration ant prostate cancer has been, or will be, treated with a chemotherapeutic agent. In r embodiment, the castration resistant prostate cancer has been, or will be, treated with radiation therapy. In another embodiment, the prostate cancer is castration resistant PCT /EP2014/054300 prostate cancer in a pre- or post-docetaxel setting. In another embodiment, the prostate cancer is castration resistant prostate cancer after cabazitaxel treatment.
In another embodiment, the prostate cancer is castration resistant prostate cancer after ent with androgen sis inhibitors, for example erone acetate. In another embodiment, the prostate cancer is tion resistant prostate cancer after treatment with en receptor antagonists, for example enzalutamide. In another embodiment, the prostate cancer is castration resistant prostate cancer after treatment with immune-modulating agents, for example Sipuleucel-T.
In another aspect, the present invention pertains to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate cancer incombination with an androgen or antagonist. In another embodiment, the prostate cancer is hormone-sensitive prostate cancer. In r embodiment, the prostate cancer is te cancer after combined androgen blockade. In another ment, the prostate cancer is prostate cancer treated with antiangiogenic y. In another embodiment the prostate cancer has been, or will be, d with a chemotherapeutic agent. In another embodiment, the prostate cancer is prostate cancer treated, or will be treated, with radiation therapy. In another embodiment, the prostate cancer is prostate cancer treated, or will be treated, with bone loss therapy, for example denosumab, and hormone ablation.
In another embodiment, the prostate cancer is castration ant prostate cancer.
In r embodiment the castration resistant prostate cancer has been, or will be, treated with a chemotherapeutic agent. In another embodiment, the castration resistant prostate cancer has been, or will be, treated with radiation y. In another embodiment, the te cancer is castration resistant prostate cancer in a pre- or post-docetaxel setting. In another embodiment, the prostate cancer is castration resistant prostate cancer after cabazitaxel treatment. In another embodiment, the prostate cancer is tion resistant prostate cancer after treatment with androgen synthesis inhibitors, for example abiraterone acetate. In another embodiment, the prostate cancer is castration resistant prostate cancer PCT /EP2014/054300 after treatment with en or antagonists, for e enzalutamide.. In another embodiment, the prostate cancer is castration ant prostate cancer after treatment with immune-modulating agents, for example Sipuleucel-T.
In another aspect, the present invention pertains to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of benign tic hyperplasia.
In another aspect, the present invention pertains to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of benign prostatic hyperplasia in combination with an androgen receptor antagonist.
An IGF receptor nist within the context of the invention is a compound that interferes with, either directly or indirectly, and reduces or blocks IGF receptor signaling. Preferably, an IGF receptor antagonist is a compound that reduces or blocks binding of IGF ligand to its receptor, or ts the tyrosine kinase activity of the IGF receptor.
In a further embodiment, the IGF receptor antagonist of the present invention is an antibody that binds to IGF ligand and thus reduces or prevents binding of the ligand to the receptor. In another embodiment, the IGF receptor antagonist is an antibody that binds to the IGF-1 receptor and thus s or prevents binding of the ligand to the or. By blocking receptor-ligand binding, ligand-induced or signaling through the tyrosine kinase activity of the receptor is reduced or prevented. Such antibodies are generally referred to as neutralizing antibodies. In another aspect, the present invention pertains to an IGF or nist that neutralizes the growth promoting properties of the insulin-like growth s, IGF- 1 and IGF-2.
The term "antibody" encompasses antibodies, antibody fragments, antibody-like molecules and conjugates with any of the above. Antibodies include, but are not limited to, poly- or monoclonal, chimeric, humanized, human, mono-, bi- or multispecific antibodies. The term "antibody" shall encompass complete PCT /EP2014/054300 immunoglobulins as they are produced by lymphocytes and for example present in blood sera, monoclonal antibodies secreted by hybridoma cell lines, polypeptides produced by inant expression in host cells, which have the binding specificity of immunoglobulins or monoclonal antibodies, and molecules which have been derived from such immunoglobulins, monoclonal antibodies, or polypeptides by further processing while retaining their g specificity. In particular, the ntibody" es te immunoglobulins comprising two heavy chains and two light chains. In another embodiment, the term asses a fragment of an immunoglobulin, like Fab fragments. In r embodiment, the term "antibody" encompasses a polypeptide having one or more variable domains derived from an immunobulin, like single chain antibodies (scFv), single domain dies, and the like.
In a further embodiment, the IGF receptor antagonist of the invention is an antibody t IGF-1, an antibody against IGF-2, an antibody binding both IGF-1 and IGF-2, an antibody against IGF-1 receptor (IGF-1R), or an inhibitor of IGF-1R tyrosine kinase activity.
In another embodiment, the IGF receptor nist is an IGF ligand antibody having heavy chain complementary ining regions of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3) and light chain determining regions of SEQ ID NO: 4 (LCDR1 ), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3).
In another embodiment, the IGF receptor antagonist is an IGF ligand antibody having heavy chain complementary determining regions of SEQ ID NO: 11 (HCDR1), SEQ ID NO: 12 (HCDR2), and SEQ ID NO: 13 (HCDR3) and light chain determining regions of SEQ ID NO: 14 (LCDR1), SEQ ID NO: 15 (LCDR2), and SEQ ID NO: 16 (LCDR3).
In another embodiment, the IGF receptor antagonist is an IGF ligand antibody having heavy chain complementary determining regions of SEQ ID NO: 21 PCT /EP2014/054300 (HCDR1), SEQ ID NO: 22 (HCDR2), and SEQ ID NO: 23 (HCDR3) and light chain determining regions of SEQ ID NO: 24 (LCDR1), SEQ ID NO: 25 (LCDR2), and SEQ ID NO: 26 (LCDR3).
In another preferred embodiment, the IGF receptor antagonist is an IGF ligand antibody having heavy chain complementary determining regions of SEQ ID NO: 31 (HCDR1), SEQ ID NO: 32 (HCDR2), and SEQ ID NO: 33 (HCDR3) and light chain determining regions of SEQ ID NO: 34 (LCDR1), SEQ ID NO: 35 ), and SEQ ID NO: 36 (LCDR3). An example of an antibody containing these complementary determining regions is designated herein as IGF mAb_1.
In another ment, the IGF receptor antagonist is an IGF ligand dy having a heavy chain le region of SEQ ID NO: 7 and a light chain variable region of SEQ ID NO: 8.
In another ment, the IGF receptor antagonist is an IGF ligand antibody having a heavy chain variable region of SEQ ID NO: 17 and a light chain variable region of SEQ ID NO: 18.
In another embodiment, the IGF receptor antagonist is an IGF ligand antibody having a heavy chain variable region of SEQ ID NO: 27 and a light chain variable region of SEQ ID NO: 28.
In another preferred embodiment, the IGF receptor antagonist is an IGF ligand antibody having a heavy chain variable region of SEQ ID NO: 37 and a light chain variable region of SEQ ID NO: 38. An example of an antibody containing these variable regions is ated herein as IGF mAb_ 1.
In another embodiment, the IGF receptor antagonist is an IGF ligand antibody having a heavy chain variable region of SEQ ID NO: 41 and a light chain variable region of SEQ ID NO: 42.
PCT /EP2014/054300 In another embodiment, the IGF or antagonist is an IGF ligand antibody having a heavy chain variable region of SEQ ID NO: 43 and a light chain variable region of SEQ ID NO: 44.
In another embodiment, the IGF receptor antagonist is an IGF ligand antibody having a heavy chain of SEQ ID NO: 9, and a light chain of SEQ ID NO: 10.
In another embodiment, the IGF receptor antagonist is an IGF ligand antibody having a heavy chain of SEQ ID NO: 19, and a light chain of SEQ ID NO: 20.
In another embodiment, the IGF receptor antagonist is an IGF ligand antibody having a heavy chain of SEQ ID NO: 29, and a light chain of SEQ ID NO: 30.
In another preferred embodiment, the IGF receptor antagonist is an IGF ligand dy having a heavy chain of SEQ ID NO: 39, and a light chain of SEQ ID NO: 40. An example of an antibody containing these heavy and light chains is designated herein as IGF mAb_1.
In another embodiment, the IGF receptor antagonist is an IGF receptor antibody having a heavy chain of SEQ ID NO: 45, and a light chain of SEQ ID NO: 46.
In another ment, the IGF or antagonist is mumab, dalotuzumab, cixutumumab, robatumumab, or ganitumab.
In another embodiment, the IGF receptor antagonist is linsitinib.
Preferably the IGF receptor antagonist is IGF mAb_1, as defined above.
Manufacture and therapeutic use of the aforementioned antibodies is disclosed in /53596, WO2007/070432, WO2008/152422, WO2008/155387, and WO2010/066868.
PCT /EP2014/054300 In one embodiment, the antibody is produced by inant expression in a mammalian host cell, purified by a series of chromatographic and nonchromatographic steps, and formulated in an aqueous buffer composition for parenteral (intravenous) infusion or injection at an dy concentration of 10 mg/ml, said buffer comprisingfor example 25 mM Na citrate pH 6, 115 mM NaCl, and 0.02 % polysorbate 20. For intravenous infusion, the pharmaceutical composition may be diluted with a physiological solution, e.g. with 0.9 % sodium chloride or G5 solution.
The antibody may be administered to the patient at a dose between 1 mg/kg to 20 mg/kg, by one or more separate administrations, or by continuous infusion, e.g. infusion over 1 hour. A typical treatment schedule y involves administration of the antibody once every week to once every three weeks. For example, a weekly dose could be 5, 10, or 15 mg/kg. Preferably, the antibody is prepared at a concentration of 10 mg/ml of IGF mAb_1. The antibody may preferably be stered to a patient as a 750 mg (up to 1000 mg) total dose by one hour i.v. infusion, to be repeated once a week until disease progression The IGF receptor antagonist is administered to the patient in combination with administration of an androgen receptor antagonist. "In ation" means that both drugs are administered to the same patient within a certain time frame to achieve a therapeutic effect caused by the combined effects of both modes of action. In one aspect, the androgen receptor antagonist is administered on the same day as the IGF receptor antagonist. In another aspect of the invention, the androgen receptor antagonist is administered one, two, three, four, five, six or seven days before or after admistration of the IGF or antagonist.
In another embodiment, both active compounds are present within the same pharmaceutical composition. Hence, in another ment, the invention ns to a pharmaceutical ition, comprising an IGF receptor antagonist and an androgen receptor antagonist, together with a ceutically acceptable carrier.
PCT /EP2014/054300 An androgen receptor antagonist (AR nist) is a compound that blocks androgen or (AR) signaling. Androgen receptor antagonists prevent androgens from expressing their biological effects on responsive tissues. Such compounds may alter the androgen pathway by blocking the respective receptors, competing for binding sites on the receptor, affecting r translocation, DNA binding of the receptor, or affecting en production. In the context of the present invention the androgen receptor antagonist can be an anti-androgen, an androgen synthesis inhibitor, a 17 a-hydroxylase/C17,20 lyase (CYP17A1) inhibitor, a 5-alpha-reductase inhibitor, a corticosteroid, a luteinizing hormonereleasing hormone (LH-RH) agonist, or an estrogen agonist.
In another embodiment, the androgen or antagonist is ide, mide, enzalutamide, bicalutamide, ketonazole, abiraterone, abiraterone acetate, orteronel, finasteride, dutasteride, bexlosteride, eride, turosteride, ride, dexamethasone, prednisone, leuprolide, goserelin, triptorelin, histrelin, or estrogen.
In another embodiment, the androgen receptor antagonist is enzalutamide (Tran et al., Science 2009, 324(5928): 787-790.) Enzalutamide can be obtained from, for e, Medivation or Astellas under the name Xtandi ®. Enzalutamide is preferably administered as a dosage of 160 mg once daily during each cycle of treatment In another embodiment, the androgen receptor antagonist is abiraterone, for example in the form of abiraterone acetate (Agarwal et al., Future Oncology 2010, 6(5): 665-679). Abieraterone can be obtained from, for example, Janssen Biotech, Inc.
Manufacture, ation, and use of the androgen receptor antagonist depends on the actual compound chosen and can be found in the state of the art.
PCT /EP2014/054300 Another ment of the invention is an en receptor antagonist for use in the treatment of prostate cancer in combination with an IGF receptor antagonist. In another embodiment the use of an androgen receptor antagonist in combination with an IGF or nist is for the treatment of benign prostatic hyperplasia. In a further embodiment, said en or antagonist is flutamide, nilutamide, enzalutamide, bicalutamide, ketonazole, abiraterone acetate, orteronel, finasteride, dutasteride, bexlosteride, izonsteride, turosteride, episteride, dexamethasone, prednisone, leuprolide, goserelin, triptorelin, histrelin, or estrogen.
Another embodiment of the invention pertains to a method of treatment of prostate neoplasia comprising administering a therapeutically effective amount of an IGF receptor antagonist to a t in need thereof, and additionally administering a therapeutically effective amount of an androgen receptor antagonist to the same patient on the same day, or one, two, three, four, five, six or seven days before or after admistration of the IGF receptor antagonist.
By "prostate neoplasia", this aspect of the ion include where the prostate neoplasia is prostate cancer, including benign and malignant tumours, and particularly castration resistant prostate ; and also benign prostatic lasia.
A "therapeutically effective amount" of the IGF or androgen receptor antagonist to be administered is the minimum amount necessary to prevent, ameliorate, or treat a prostate neoplasia, in particular castration-resistant prostate cancer, or benign prostatic hyperplasia.
In another embodiment, the invention pertains to the use of an IGF receptor antagonist for the manufacture of a medicament for the ent of prostate neoplasia , wherein the IGF receptor antagonist is to be used in combination with an androgen receptor antagonist.
PCT /EP2014/054300 By "prostate neoplasia", this aspect of the invention include where the te neoplasia is prostate cancer, including benign and malignant tumours, and particularly castration resistant prostate cancer; and also benign tic hyperplasia.
In another embodiment, the invention pertains to the use of an en receptor nist for the manufacture of a medicament for the treatment of prostate cancer neoplasia, wherein the androgen receptor antagonist is to be used in combination with an IGF receptor antagonist.
By "prostate neoplasia", this aspect of the invention include where the prostate neoplasia is prostate , ing benign and malignant tumours, and particularly tion resistant prostate cancer; and also benign prostatic hyperplasia.
EXAMPLES Materials and Methods Compounds IGF mAb_1 is an antibody against IGF ligand having a heavy chain of SEQ ID NO: 39 and a light chain of SEQ ID NO: 40. Its manufacture has been disclosed in WO 2010/066868.
IGF mAb_2 is an antibody against IGF ligand having a heavy chain of SEQ ID NO: 29 and a light chain of SEQ ID NO: 30. Its manufacture has been disclosed in WO 2010/066868.
PCT /EP2014/054300 Cell culture DU-145 (ATCC, HTB-81), BM-1604 (DSMZ, ACC 298), PC-3 (ATCC, CRL-1435), 22Rv1 (ATCC, CRL-2505), LNCaP (ATCC, CRL-1740), and DUCaP cells (generated in the lab of Prof KJ. Pienta, Hallym University, College of Medicine, Seoul, Korea; Lee YG et al., In Vivo 2001 ;15(2):157-62) were cultivated in RPMI 1640 growth medium (GIBCO, #31870) supplemented with 10 % heat inactivated fetal calf serum (FCS; JRH, #12103), and 2 mM L-glutamine (GIBCO, #25030); NCI-H660 (ATCC, CRL-5813) were grown in RPMI supplemented with 5% FCS, 4 mM L-glutamine, 5 µg/ml insulin, 0.01 mg/ml transferrin, 30 nM sodium selenite, nM beta estradiol and 10 nM hydrocortisone. C4-2 and C4-2b (both licensed from MD Anderson Cancer Center; Thalmann GN et al., Cancer Res. 1994; 54:2577-2581) and VCaP (ATCC, CRL-2876) were cultivated in DMEM , #12-604F) supplemented with 10 % heat inactivated FCS, 2 mM L-glutamine and R1881 (Sigma, #R0908; VCaP with 0.1 nM and 4-2b with 1 nM). -2b (ATCC, CRL-2422) were grown in F-12K , #21127) supplemented with 20% nactivated FCS, 25 ng/ml cholera toxin, 0.005 mM ethanolamine, 100 pg/ml hydrocortisone, and 45 nM ous acid. Bob cells (ECACC, #10021102) were cultured in keratinocyte-SFM (lnvitrogen, #37010-022) supplemented with prequalified human recombinant epidermal growth factor 1-53, bovine pituitary extract and glutamine, 2 ng/ml leukemia inhibitory , 2 ng/ml stem cell factor, 100 ng/ml cholera toxin, and 1 ng/ml ocyte macrophage colony stimulating factor. Shmac 4 , #10112302), Shmac 5 (ECACC, #10112303) and P4E6 cells (ECACC, 301) were grown in Stemline Keratinocyte Medium II (Sigma, #S0196) with Stemline Keratinocyte Growth Supplement (Sigma, #S9945), 2mM L-glutamine and 2% FCS. The cells were maintained in 75 cm2 tissue culture flasks (Nunc, #178905) at 37°C in 5 % CO2 in a humidified atmosphere. 2D Cell Proliferation Assay The following method was used to determine the inhibitory effect of IGF ligandneutralizing mAbs and androgen signaling inhibitors on the growth of prostate WO 35611 PCT /EP2014/054300 cancer cell lines. Assays were performed in cell growth medium containing 10% serum.
Adherent cells were detached with trypsin/EDTA solution (GIBCO, #043-9031FU), resuspended in growth medium, centrifuged, resuspended in assay medium (supplemented with 10% heat inactivated FCS and 2 mM amine) and diluted to 5,000 - 40,000 cells per ml. 100 µL/well cell suspension was added to each well of a sterile flat-bottom white 96-well plate (PerkinElmer, #6005280) and plates were incubated overnight in a humidified incubator set at +37°C and 5% CO2. On the next day supernatants were aspirated and 35 µL/well assay medium was added to all wells.
Serial dilutions of IGF mAb_1 and mAb_2 (1 µM highest concentration), MDV- 3100 (10 µM highest concentration), abiraterone e (100 µM highest concentration) were prepared on a separate plate in assay medium (no growth factors or hormones supplemented). All agents were tested as single agents or in combination. All samples were tested in triplicate wells (100 µL/well assay). Plates were incubated for 5 days in a humidified incubator at +37°C and 5% CO2. After this incubation period, CellTiter-Glo buffer, substrate and test plates were brated to RT. CellTiter-Glo is a bioluminescent assay ga, #G7571) designed to determine the number of viable cells in culture, in which the generation of a luminescent signal is proportional to the amount of ATP present in cells. 100 µL of freshly mixed CellTiter-Glo reagent was added to each well. After 2 min on an l shaker (MTS 2/4, IKA) and 10 min incubation at RT, luminescence was recorded (luminescence reader (Genios Pro, Tecan or Victor X4, Perkin Elmer), integration time 1 sec).
Generation of Cell Lysates and lmmunoblotting One x 106 and 4 x 106 cells were plated in 6-well plates and 10 cm dishes, tively, in medium containing 10% heat-inactivated FCS and after over night incubation the cells were treated with 1 µM of MDV-3100 and 100 nM of IGF mAb_1 or a combination of antibody and AR signaling inhibitor. After 24 hours the PCT /EP2014/054300 cells were lyzed on the plates, total protein was isolated and protein concentration was determined by Bradford assay. Cell lysates were snap frozen and stored at - 80°C.
Western blotting was performed loading 30-50 µg of total protein s on a 4- 12% Bis-Tris PAG (Bio Rad) and blotting with the Bio Rad blot® Turbo system using a PVDF ne. Membranes were incubated over night at 4°C with antibodies against the following proteins: IGF-1R beta (#3027, Cell Signaling; 1:1000), p-S473 AKT (#4060, Cell Signaling; 1:2000), AKT (#9272, Cell Signaling; 1:1000), PTEN (#9559, Cell Signaling; 1:1000), AR (N-20, # , Santa Cruz; , and GAPDH (#7298, Cell Signaling; 1 :1000)(which served as loading control). Cell cycle regulators and markers of proliferation and apoptosis were analyzed using the following antibodies: p21 Waf1/Cip1 (12D1;#2947, Cell ing; 1:1000), CDK2 (78B2; #2546, Cell Signaling; 1:1000), Cyclin E (C-19; sc-198, Santa Cruz; 1:1000), PCNA (#2586, Cell Signaling; 1:2000), and PARP (#9542, Cell Signaling; 1:1000).
Antibody ons were prepared in 5% BSA or 5% non-fat dry milk in 5% 0 (TBS-T). Following washes in TBS-T membranes were incubated with a polyclonal HRP-conjugated goat anti-rabbit secondary antibody (DAKO, ) for 1 hour and after further washes in TBS-T antibody reactivity was detected by means of EGL/Super EGL (GE Healthcare) and exposure on lmageQuant LAS4000. For the detection of total protein levels, membranes incubated with antiphospho antibodies were stripped in Restore Western Blot Stripping Buffer (Thermo, #21059) for 15-20 min, blocked, and incubated with the antibody against the total protein before the membrane was processed as described above.
Cell Cycle Analysis using Flow Cytometry 4 x 105 VCaP cells were treated with 1 µM of IGF mAb_ 1 and 10 µM of MDV- 3100, and the combination of both agents, and incubated in 6-well plates at 37°C for 24 h, 48 h and 72 h. uently, the supernatant was transferred to FAGS tubes, nt cells were detached with trypsin and collected in the respective PCT 4/054300 FAGS tubes. After centrifugation, the medium was discarded and the cell pellet was fixed in ice-cold 70% ethanol for a minimum of 2 h at 4 °C. After removing the ethanol entirely, fixed cells were stained with propidium iodide (10 µg/ml; Sigma; P4864-10ml) in a hypotonic buffer solution (0.1 % sodium citrate, 0.1 % (v/v) triton X-100, 100 µg/ml DNase-free RNase A) and incubated in the dark at room temperature for 30 minutes. Cells were analyzed using the Becton Dickinson FAGS Canto II Flow ter and data was evaluated with the FAGS Diva software.
Thymidine Incorporation Assay VCaP cells were treated with 1 µM of IGF mAb_1 and 10 µM of MDV-3100 and the combination of both agents and incubated as triplicates in ottom l plates for 96 hours at a density of 5 x 104 cells per well, in the absence of R1881.
For the last 24 hours of incubation, H-thymidine (0.4 µCi/well; PerkinElmer, NET355001 MC) was added. Afterwards, the plates were frozen and incubated at - °C for 24h. For harvesting, the plates were thawed and 40 µL Trypsin was added to each well to detach the cell fragments. The suspension was transferred to filter plates. The plates were then washed three times with distilled water and dried at 60°C for 3h. 25 µL per well Microscint were added and the proliferation rate was ined by measuring thymidine incorporation (CPM; counts per ) using a liquid scintillation counter (1450 Microbeta Wallac Trilux, Perkin Elmer).
Analysis of Cellular Doubling Time 3 x 105 cells/well VCaP cells were seeded in 2 ml cell culture medium per well. 24 hrs post g the cell culture medium was removed and replaced with DMEM +10% FCS without R1881. 24 hr following the medium change the pre-treatment wells were harvested and counted with the Beckman Coulter™ Vi-CELL XR 2.03, and 10 µM of MDV-3100 was added to the remaining cells. Four times every 24 hr VCaP cell number was determined in 3 wells for each time point. The mean value was calculated from these triplicates. To determine the generation time, following formula is used: PCT /EP2014/054300 . . log2 :.: rnltin1tion hours [h] [h generation time] = 1og,�·- 1og.�o . . _ log2 )( rnltimtion hours [h] [h generationtm e -] 1 1og,v- • • 1ogno �, No= cell count at TO N= cell count after cultivation Assessment of Caspase 3 Activity To acquire live cell images of cells undergoing caspase-3/7 mediated apoptosis upon treatment with different concentrations of MDV-3100, IGF mAb_1, and the combination of both agents, the CellPlayer™ 96-Well Kinetic Caspase-3/7 Reagent (Essen Bioscience; # 4440) was used. 50000 VCaP cells/ 100µ1/ well were seeded and treated on the next day with the respective concentrations of both agents in growth medium in the absence of R1881. The Caspase-3/7 reagent was ed to a final concentration of 5 µM in 100 µI per well of growth medium and added to the . The plate was placed within a microplate tray into the lncuCyte™ 2011A and 3 images per well were acquired every 4 hours for 7 days using the phase st and fluorescence channels.
Example 1 Inhibitory effect of IGF and AR ing blockade on prostate cancer cell proliferation In order to test the anti-proliferative effects of the combination of AR and IGF-1/2 inhibition, 10 different prostate cancer cell lines (Bob, C4-2, C2B, DUCaP, MDA PCa 2b, P4E6, PC-3, Shmac 4, Shmac 5, VCaP) were treated with the AR antagonist MDV-3100 and fully human monoclonal antibodies against the IGF ligands (IGF mAb_1 and IGF mAb_2), as single agents and in combination, in 2D cell proliferation assays (Table 1). Three of the tested cell lines (VCaP and DUCaP - both cell lines were derived from the same te cancer patient from different sites of asis, and MDA PCa 2b) showed single agent anti-proliferative PCT /EP2014/054300 response to both the AR and IGF signaling inhibition alone, and an enhanced effect when ed (Figure 1).
Example 2 Inhibitory effect of IGF signaling and androgen synthesis blockade on prostate cancer cell proliferation As a second approach to test the combination potential of androgen and IGF signaling inhibition, 8 different prostate cancer cell lines (22Rv1, BM 1604, DU- 145, DUCaP, LNCaP, MDA PCa 2b, PC-3, VCaP) were treated with abiraterone e, which selectively inhibits CYP17A and thus de novo synthesis of androgens, alone and in combination with IGF-ligand neutralizing monoclonal antibodies (IGF mAb_1 and IGF mAb_2). The results from these assays also identified VCaP, MDA PCa 2b, and DUCaP cells to be the only cell lines which are responsive to both single agent and combination treatments. Treatment with erone acetate, however, implies autocrine androgen production by the tumor cells for abiraterone acetate to show anti-proliferative effects. This might limit the number of cells sensitive to abiraterone acetate ent. Results of 2D and 3D eration assays for VCaP and 2D assays of MDA PCa 2b and DUCaP cells are shown in Figure 2. These data t that the single agent effects of abiraterone acetate on cell proliferation can be ed by the combination with antibodies neutralizing IGF s.
Example 3 The presence of androgen receptor and IGF-1 R as well as expression of PTEN and wt PIK3CA characterizes prostate cancer cells sensitive to the combination of androgen and IGF signaling inhibitors Figure 3 shows signaling protein expression in the VCaP, MDA PCa 2b, and DUCaP cell lines, which are sensitive to AR and IGF signaling inhibition, in comparison to the insensitive cell line PC-3. Cells were treated with MDV-3100 and IGF mAb_1 as single agents, or in combination, for 24 hours and protein lysates were ed to untreated controls for protein expression of IGF-1R, AR, PCT /EP2014/054300 PTEN and AKT, and for phosphorylation of AKT-Ser473. Responsive cell lines expressed wt AR, IGF-1 R, and PTEN. These characteristics were not present in PC-3 or the other tested cell lines which did not show an anti-proliferative responce to either one of the single agent treatments or the combination of both agents (Table 1 ).
These results indicate that in the presence of androgen receptor, IGF-1 R, and expression of PTEN (and wt PIK3CA), the combination of androgen and IGF signaling inhibitors results in an increased efficacy in blocking prostate cancer cell proliferation in vitro.
Example 4 Prolonged AKT orylation inhibition following combined treatment of MDV-3100 and IGF mAb 1 The effects of MDV-3100 and IGF ligand mAb (IGF mAb_1) as single agents, and combined treatment, on the tion of AKT phosphorylation were analyzed by Western blot from 4h until 120h of treatment. The combination of both agents resulted in a more complete and longer g inhibition of AKT orylation than the antibody treatment alone (Figure 4).
Combined treatment with IGF mAb_1 and MDV-3100 leads to a istic effect on apoptotic induction in VCaP cells In support of the data shown in Figure 1, results from tritiated thymidine incorporation assays shown in Figure 5 demonstrates that both MDV-3100 and IGF mAb_1 alone have an inhibitory effect on cell proliferation (approximately 50%), r, the combination of both agents was much more ive. ent of VCaP cells with IGF mAb 1 alone led to a modest increase in apoptosis as assessed by phase contrast microscopy (Figure 6A), caspase 3 activity (Figure 7), FAGS-based cell cycle analysis (Figure 8), and PARP cleavage (Figure 9). In contrast, the reduced cell number seen after treatment with MDV- PCT /EP2014/054300 3100 alone (Figure 6A) was due to prolonged cellular doubling time (Figure 6B). 00 did not induce caspase 3 activity (Figure 7), sub-G1 apoptosis cell population (Figure 8), or PARP cleavage e 9). However, when IGF mAb_1 and MDV-3100 were combined a synergistic effect on caspase 3 activity was observed (Figure 7), in addition to enhanced sub-G1 apoptotic cell population (Figure 8) and cleaved PARP (Figure 9).
Example 6: Proposed study of IGF mAb_1 in combination with enzalutamide Introduction The study proposed here investigates the safety and anti-tumour activity of IGF mAb_ 1 in combination with enzalutamide, compared to enzalutamide given alone, in CRPC patients This randomised, open label, study will be conducted to explore the anti-tumour activity and safety profile of the combination of IGF mAb_ 1 and enzalutamide (Arm A), compared to enzalutamide (Arm B). A tolerability and safety phase lb will be performed to determine the maximum tolerated dose (MTD), and/or recommended phase II dose, in addition to any safety issues before commencement of the ised trial..
IGF mAb_ 1 will be administered weekly in 28 day cycles of ent by a one hour intravenous on at the start of each treatment cycle. Enzalutamide will be administered daily by uous oral dosing during each treatment cycle.
Background IGF mAb_ 1 is a fully human monoclonal dy (HumAb) of the lgG1 isotype.
The Ab binds with high affinity to IGF-1 and IGF-2, and potently neutralizes the erative and prosurvival cellular signaling triggered by both proteins.
PCT 4/054300 Enzalutamide is an en receptor nist that acts on different steps in the androgen or ling pathway. The al name is 4-{3-[4-cyano (trifluoromethyl )phenyl]-5,5-dimethyloxosulfanylideneimidazolidinyl} fluoro-N-methylbenzamide. The molecular weight is 464.44 and molecular formula is C21H16F4N4O2S. Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) Administration IGF mAb_ 1 will be administered weekly in 28 day cycles of treatment, by a one hour intravenous infusion at the start of each treatment cycle. Enzalutamide will be administered daily by continuous oral dosing during each treatment cycle.
Selection of trial population A total of up to approximately 140 patients may be recruited into the study.
Approximately 15-18 patients will be entered into the part I tolerability and safety phase of the study to ensure the safety of the combination therapy and determine the part II recommended dose. In part II of the study, 120 patients will be randomised onto one of the two study arms, with 60 patients randomised to each arm (Arm 8=60, Arm 8=60).
Part I of the study will be performed in 3 or more centres. Part II of the study will be performed in 10 or more centres globally.
A log of all patients included into the study (i.e. having given informed consent) will be maintained in the ISF at the investigational site irrespective of whether they have been treated with investigational drug or not.
PCT /EP2014/054300 Main sis for study entry Patients to be included in this study must have diagnosed and histologically, or cytologically, confirmed metastatic CRPC and have received and progressed after one line of docetaxol treatment. Patients may, or may not, have received and failed prior abiraterone, or taxel treatment, in any setting.
Inclusion criteria 1. The patient has ogically, or cytologically, confirmed adenocarcinoma of the prostate. 2. Male patient aged � 18 years old. 3. Patients with radiographic evidence of atic prostate cancer (stage M1 or D2). Distant metastases evaluable by radionuclide bone scan, CT scan, or MRI within 28 days of start of study treatment. 4. ts who have disease progression (biochemical, clinical or radiographic) while receiving docetaxel, or within 120 days of completing docetaxel-based chemotherapy and in the opinion of the investigator is unlikely to derive icant t from additional docetaxel-based therapy, or was intolerant to therapy with this agent.
. Patients must have evidence of progressive disease defined as at least one of the following: a. Progressive measurable disease: using tional solid tumour criteria RECIST 1.1. b. Bone scan progression: at least two new lesions on bone scan. c. Increasing PSA: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2. 6. Patients with a PSA � 2 ng/ml.
PCT /EP2014/054300 7. Patients with prior surgical or medical tion with a serum testosterone of <50 ng/ml. If the method of castration is luteinizing hormone releasing level hormone (LHRH) agonists, the patient must be willing to continue the use of LHRH ts during protocol treatment. 8. Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1 or 2. 9. Patients have te hematologic function (absolute neutrophil count [ANG] �1500/ul, obin �9 g/dl, and platelets �100,000/ul).
. Patients have adequate hepatic function (bilirubin::;; 1.5 times the upper limit of normal (ULN)], aspartate transaminase [AST] and e transaminase [ALT]::;; 3 times the ULN, or::;; 5 times the ULN if liver metastases are present). 11. Adequate renal function (creatinine ::;; 1.5 x ULN or calculated creatinine clearance> 40 ml/min). 12. A urinary protein of::;; 1+ on ck or routine urinalysis (UA). If urine ck or routine analysis indicates � 2+ proteinuria, then a r urine must be collected and must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study. 13. Adequate coagulation function (an international normalized ratio [INR] ::;; 1.5 and a partial thromboplastin time [PTT] ::;; 5 seconds above the ULN [unless on oral anticoagulant therapy]). Patients receiving full-dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (except warfarin, which is not permitted). 14. Fasting plasma glucose < 8.9 mmol/L (< 160 mg/dl) or HbA1c < 8.0%.
Exclusion criteria 1. Patients that have received more than two prior taxane based cytotoxic chemotherapy regimen for metastatic disease. Patients who have had a ent break from docetaxol ed by a second or third docetaxel-based regimen, with subsequent disease progression, are eligible. 2. ts that have received prior enzalutamide in any setting will not be eligible.
PCT /EP2014/054300 3. Patients who have received abiraterone, or cabazitaxel treatment, within 4 weeks before start of study treatment. 4. Patient that have received prior therapy with mitoxantrone for advanced prostate cancer (prior adjuvant therapy with mitoxantrone is permitted). 5. Patients that have been treated with any of the following within 4 weeks of starting trial medication: chemotherapy, immunotherapy, biological therapies, molecular targeted, hormone therapy, radiotherapy (except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within 2 weeks prior to study treatment). 6. Use of any investigational drug within 4 weeks before start of trial treatment or concomitantly with this trial. 7. ts that have been treated with strong CYP2C8 inhibitors; strong or moderate CYP3A4 or CYP2C8 inducers; CYP3A4, CYP2C9 and CYP2C19 substrates with a narrow therapeutic index, within 4 weeks of starting the trial. 8.Patients with a history of symptomatic tive heart failure or has a prestudy echocardiogram or ated acquisition (MUGA) scan with left ventricular ejection on (LVEF) that is � 10% below the LLN. 9. QTcF prolongation> 450 ms or QT prolongation deemed clinically relevant by the investigator (e.g., congenital long QT syndrome).The QTcF will be calculated as the mean of the 3 ECGs taken at ing.
. Patients with small cell or neuroendocrine tumours. 11. Patients with known or suspected leptomeningeal ases. 12. Uncontrolled or poorly controlled ension. 13. Patients with poorly controlled diabetes mellitus. Patients with a history of diabetes are allowed to participate, provided that their blood glucose is within normal range (fasting < 160 mg/dl or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition. 14. Known human immunodeficiency virus infection or acquired immunodeficiency me-related illness. 15. Patients with epilepsy, seizures, or posing factors for seizure as judged by the investigator. 16. ts unable to comply with the ol as judged by the investigator.
PCT /EP2014/054300 17. Active alcohol or active drug abuse as judged by the investigator. 18.A history of allergy to human monoclonal antibodies. 19. Prior therapy with agents targeting IGF and/or IGFR pathway.
. Patients who are sexually active and unwilling to use a lly acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine s or omized partner for participating females, condoms for participating males) during the trial and for at least three months after end of active therapy. Men unwilling to agree to not donate sperm while on trial drug and up to 6 months following the last dose of trial drug.
Additional ion criteria for part II: 21. For patients that are to undergo the optional tumour biopsy, a history of a hereditary bleeding disorder, or clinically relevant major bleeding event in the past 6 months, as judged by the investigator.
Treatments to be stered nce: IGF mAb_ 1 human monoclonal antibody Pharmaceutical form: Liquid formulation Source: Boehringer lngelheim Pharma GmbH & Co. KG Unit strength: 10 mg/ml of IGF mAb_1 supplied in 20 ml vials.
Appropriate dose of IGF mAb_1 will be diluted in logical sodium chloride solution (0.9%).
Duration of use: One hour at the start of each week (Day 1, 8, 15 and 22) of a 28 day cycle of treatment until disease progression or undue toxicities. Infusion duration may be extended to over one hour in case of infusion reaction or adverse events.
Route of administration: Intravenous Starting dose: 750 mg (up to 1000 mg) total dose by one hour i.v. infusion PCT /EP2014/054300 Additional information: Dose will be ed during part I tolerability/safety and dose finding phase nce: Enzalutamide (Xtandi®) Pharmaceutical form: Liquid-filled soft gelatin capsule Source: Astellas Unit strength: 40 mg Duration of use: 160 mg once daily during each cycle of treatment Route of administration: Oral Starting dose: 160 mg once daily Additional information: Dose will be adjusted during part I tolerability /safety and dose finding phase from that stated in the summary of product teristics (SPC).
Table 1 gives an overview of the ons, protein expression and effects of androgen and IGF signaling inhibition observed in the 15 different tested prostate cancer cell lines.
Table 1 ., c c � :,,: Q. .... u C ..0 ::, u �� � a: � ;e'.j:i E oi :c u !:2 a: E: Q. E: m :i: .29 :c E 00 .c < ;;: f- � "' ·= � .29 .c"' ·= LJ.J < "iii ·-C E 0 0u <.J LJ.J LJ.J 22Rvl + ~ + - + ~ ~ (Q546R) BM-1604 - + ~ wt - - ~ ~ derived from DU-145 Bob - ~ ~ - - - - Spontaneously immortalized CRPC (1391H) C4-2 + + - wt - + - - LNCaP d cell lines (xenograft in castrated mice) C4-2B + + - wt - + - - PCT /EP2014/054300 DU 145 - + - wt - - ~ - Isolated from ent metastases * DUCaP + + + wt ERG + + +++ from same PCa patient as VCaP LNCap.FGC + + - wt - + - - *MDAPCa 2b + + + wt - + + ++ NCI-H660 - ~ - n.d. ERG - n.d. n.d.
P4E6 - + ~ wt - - - - PC-3 - + - wt - - - - Shmac4 - + ~ wt - - - - Shmac5 - + ~ wt - - - - Isolated from different metastases *VCaP + + + wt ERG + + +++ from same PCa patient as DUCaP Cell lines labeled with an asterisk represent responsive cell lines expressing wt AR, wt Pl3K, PTEN and .
Abbreviations: AR= androgen receptor; IGF-1R = Insulin-like growth factor 1 receptor; mut = mutated; n.d. = not determined; wt= wild type
Claims (8)
1. Use of an insulin-like growth factor (IGF) receptor antagonist in the manufacture of a ment for the treatment of prostate neoplasia, wherein the medicament is formulated for administration in combination with an en or antagonist selected from enzalutamide and abiraterone acetate, wherein the IGF receptor antagonist is an antibody having heavy chain complementary determining regions of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3) and light chain determining regions of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3), or an antibody having heavy chain complementary determining regions of SEQ ID NO: 11 (HCDR1), SEQ ID NO: 12 (HCDR2), and SEQ ID NO: 13 (HCDR3) and light chain determining regions of SEQ ID NO: 14 (LCDR1), SEQ ID NO: 15 (LCDR2), and SEQ ID NO: 16 (LCDR3), or an antibody having heavy chain complementary ining regions of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2), and SEQ ID NO: 23 (HCDR3) and light chain determining regions of SEQ ID NO: 24 (LCDR1), SEQ ID NO: 25 (LCDR2), and SEQ ID NO: 26 (LCDR3), ), or an antibody having heavy chain complementary determining s of SEQ ID NO: 31 (HCDR1), SEQ ID NO: 32 (HCDR2), and SEQ ID NO: 33 (HCDR3) and light chain determining s of SEQ ID NO: 34 (LCDR1), SEQ ID NO: 35 (LCDR2), and SEQ ID NO: 36 (LCDR3), or an antibody having a heavy chain variable region of SEQ ID NO: 7 and a light chain variable region of SEQ ID NO: 8, or an antibody having a heavy chain variable region of SEQ ID NO: 17 and a light chain le region of SEQ ID NO: 18, ), or an antibody having a heavy chain variable region of SEQ ID NO: 27 and a light chain variable region of SEQ ID NO: 28, ), or an antibody having a heavy chain variable region of SEQ ID NO: 37 and a light chain le region of SEQ ID NO: 38, ), or an antibody having a heavy chain variable region of SEQ ID NO: 41 and a light chain variable region of SEQ ID NO: 42, ), or an antibody having a heavy chain variable region of SEQ ID NO: 43 and a light chain variable region of SEQ ID NO: 44, or an dy having a heavy chain of SEQ ID NO: 9, and a light chain of SEQ ID NO: 10, or an antibody having a heavy chain of SEQ ID NO: 19, and a light chain of SEQ ID NO: 20, or an antibody having a heavy chain of SEQ ID NO: 29, and a light chain of SEQ ID NO: 30, or an antibody having a heavy chain of SEQ ID NO: 39, and a light chain of SEQ ID NO: 40.
2. The use of claim 1 wherein the prostate neoplasia, is benign prostatic lasia (BPH) or prostate cancer.
3. The use of claim 2 wherein the prostate cancer, is castration resistant prostate cancer.
4. The use of any one of claims 1 to 3, wherein the antibody has a heavy chain of SEQ ID NO: 39, and a light chain of SEQ ID NO: 40.
5. Use of an androgen or antagonist selected from enzalutamide and erone acetate in the manufacture of a ment for the treatment of prostate neoplasia, wherein the medicament is ated for administration in combination with an IGF receptor antagonist, wherein the IGF receptor antagonist is an antibody having heavy chain complementary determining regions of SEQ ID NO: 1 (HCDR1), SEQ ID NO: 2 (HCDR2), and SEQ ID NO: 3 (HCDR3) and light chain determining regions of SEQ ID NO: 4 (LCDR1), SEQ ID NO: 5 (LCDR2), and SEQ ID NO: 6 (LCDR3), or an antibody having heavy chain complementary determining regions of SEQ ID NO: 11 (HCDR1), SEQ ID NO: 12 (HCDR2), and SEQ ID NO: 13 (HCDR3) and light chain determining regions of SEQ ID NO: 14 (LCDR1), SEQ ID NO: 15 (LCDR2), and SEQ ID NO: 16 (LCDR3), or an antibody having heavy chain complementary ining regions of SEQ ID NO: 21 ), SEQ ID NO: 22 ), and SEQ ID NO: 23 (HCDR3) and light chain determining regions of SEQ ID NO: 24 (LCDR1), SEQ ID NO: 25 (LCDR2), and SEQ ID NO: 26 (LCDR3), ), or an dy having heavy chain complementary determining regions of SEQ ID NO: 31 (HCDR1), SEQ ID NO: 32 (HCDR2), and SEQ ID NO: 33 (HCDR3) and light chain determining regions of SEQ ID NO: 34 (LCDR1), SEQ ID NO: 35 (LCDR2), and SEQ ID NO: 36 (LCDR3), or an antibody having a heavy chain variable region of SEQ ID NO: 7 and a light chain variable region of SEQ ID NO: 8, or an antibody having a heavy chain variable region of SEQ ID NO: 17 and a light chain variable region of SEQ ID NO: 18, ), or an antibody having a heavy chain variable region of SEQ ID NO: 27 and a light chain variable region of SEQ ID NO: 28, ), or an antibody having a heavy chain variable region of SEQ ID NO: 37 and a light chain variable region of SEQ ID NO: 38, ), or an antibody having a heavy chain variable region of SEQ ID NO: 41 and a light chain variable region of SEQ ID NO: 42, ), or an antibody having a heavy chain variable region of SEQ ID NO: 43 and a light chain variable region of SEQ ID NO: 44, or an antibody having a heavy chain of SEQ ID NO: 9, and a light chain of SEQ ID NO: 10, or an antibody having a heavy chain of SEQ ID NO: 19, and a light chain of SEQ ID NO: 20, or an antibody having a heavy chain of SEQ ID NO: 29, and a light chain of SEQ ID NO: 30, or an dy having a heavy chain of SEQ ID NO: 39, and a light chain of SEQ ID NO: 40.
6. The use of claim 5 wherein the te neoplasia, is benign prostatic hyperplasia (BPH) or prostate cancer.
7. The use of claim 6 wherein the prostate cancer, is castration resistant prostate cancer.
8. The use of any one of claims 5 to 7, wherein the antibody has a heavy chain of SEQ ID NO: 39, and a light chain of SEQ ID NO: 40. Boehringer Ingelheim International GmbH By the Attorneys for the Applicant SPRUSON & FERGUSON Per:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13158228.0 | 2013-03-07 | ||
EP13158228 | 2013-03-07 | ||
PCT/EP2014/054300 WO2014135611A1 (en) | 2013-03-07 | 2014-03-06 | Combination therapy for neoplasia treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ711210A NZ711210A (en) | 2020-11-27 |
NZ711210B2 true NZ711210B2 (en) | 2021-03-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10377828B2 (en) | Combination therapy for neoplasia treatment | |
CN109196121A (en) | Treatment and diagnostic method for cancer | |
CN106659772B (en) | Compositions and methods for modulating renalase in the treatment of diseases and disorders | |
KR20150130318A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
BR112012032008B1 (en) | S100A4 ANTIBODIES, HYBRIDOMA CELL LINE, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD AND KIT FOR DIAGNOSTICING CANCER OR A DISEASE ASSOCIATED WITH INFLAMMATION | |
JPWO2007132867A1 (en) | Preventive and therapeutic agents for cancer | |
AU2022218493A1 (en) | Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same | |
KR20210046716A (en) | Treatment of triple negative breast cancer by targeted TGF-β inhibition | |
BR112019021495A2 (en) | AMHRII CONNECTION COMPOUNDS FOR PREVENTING OR TREATING LUNG CANCERS | |
WO2011057064A1 (en) | Igf1r inhibitor based treatment of prostate cancer | |
US10294295B2 (en) | Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment | |
US20220056123A1 (en) | Use of il-1beta binding antibodies | |
NZ711210B2 (en) | Combination therapy for neoplasia treatment | |
US20150037336A1 (en) | Combination of hb-egf binding protein and egfr inhibitor | |
TW201532613A (en) | Combination therapy for NEOPLASIA treatment | |
US20150023920A1 (en) | Novel compositions and methods for preventing or treating cancer metastasis | |
US11020478B2 (en) | Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment | |
TW202402791A (en) | Use of anti-il-27 antibodies | |
CN117500522A (en) | Anti-galectin-9 antibodies and therapeutic uses thereof | |
WO2020128613A1 (en) | Use of il-1beta binding antibodies | |
CN117580589A (en) | Combination of anti-galectin-9 antibodies and chemotherapeutic agents for use in cancer therapy | |
BRPI0622074B1 (en) | ANTIBODY OR ISOLATED HUMAN ANTIBODY FRAGMENT SPECIFIC TO PDGFR-ALPHA, POLYNUCLEOTIDE AND EXPRESSION VECTOR |